Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3295121 | 0.90 | HTT (0.62) | HTTLMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL9772171 | 0.90 | HTT (0.60) | HTTLMNASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL3693228 | 0.89 | HTT (0.61) | HTTLMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL3823557 | 0.86 | CTSL (0.54) | HTTLMNASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL17377400 | 0.86 | HTT (0.64) | HTTLMNASMN1; SMN2L3MBTL1MEN1 | |
| Glycolic Acid SCHEMBL27895348 | 0.85 | HTT (0.60) | HTTLMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL21559798 | 0.85 | HTT (0.72) | HTTLMNASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL18765240 | 0.85 | SIRT2 (0.60) | HTTLMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL15382021 | 0.85 | HTT (0.62) | HTTLMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL17495253 | 0.84 | HTT (0.56) | HTTLMNASMN1; SMN2L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112424195-B | Fused lactam derivatives | 住友制药株式会社 | 2025-03-25 | — | — | CN | disclosed |
| US-20250084090-A1 | SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY | Sumitomo Pharma Co., Ltd. (JP) | 2025-03-13 | — | — | US | disclosed |
| US-12180213-B2 | Substituted pyrazoles showing serotonin 5-HT receptor activity | SUMITOMO PHARMA CO. LTD. (JP) | 2024-12-31 | — | — | US | disclosed |
| US-20230008875-A1 | SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-12 | — | — | US | disclosed |
| US-20230008875-A1 | SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-12 | — | — | US | disclosed |
| US-11466007-B2 | Substituted lactams showing serotonin 5-HT receptor activity | Sumitomo Pharma Co., Ltd. (JP) | 2022-10-11 | — | — | US | disclosed |
| EP-3828182-A1 | FUSED RING LACTAM DERIVATIVES | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-06-02 | — | — | EP | disclosed |
| EP-3828182-A1 | FUSED RING LACTAM DERIVATIVES | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-06-02 | — | — | EP | disclosed |
| CN-112424195-A | Condensed lactam derivatives | 大日本住友制药株式会社 | 2021-02-26 | — | — | CN | disclosed |
| US-10745401-B2 | Condensed lactam derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-18 | — | — | US | disclosed |
| EP-1725544-A1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | US | disclosed |
| WO-2005090333-A1 | 3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-0737751-B1 | Method for producing optically active ester of gamma-substituted-beta-hydroxybutyric acid | MITSUBISHI CHEM CORP (JP) | 2001-08-01 | — | — | EP | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| US-5700670-A | TREATING MICROORGANISM CULTURE WITH ALKYL ESTER OF GAMMA-SUBSTITUTED ACETOACETIC ACID FOR STEREOSPECIFIC REDUCTION OF CARBONYL GROUP TO HYDROXYL GROUP YIELDS GAMMA-SUBSTITUTED 3-HYDROXYBUTYRIC ACID | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-12-23 | — | — | US | disclosed |
| US-5599954-A | N-substituted-7-amino-5-hydroxy-3-oxoheptanoic acid derivatives and method for producing the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1997-02-04 | — | — | US | disclosed |
| EP-0737751-A2 | Method for producing optically active ester of gamma-substituted-beta-hydroxybutyric acid | Mitsubishi Chemical Corporation (JP) | 1996-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084090-A1 | SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY | HTR1A, HTR5A, TPH1 | HTT 842/4885LMNA 4571/4885SMN1; SMN2 1775/4885 |
| US-12180213-B2 | Substituted pyrazoles showing serotonin 5-HT receptor activity | HTR5A, HTR1A, TPH1 | HTT 357/4885LMNA 4739/4885SMN1; SMN2 3506/4885 |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | HTT 2241/4885LMNA 279/4885SMN1; SMN2 4142/4885 |
| US-10745401-B2 | Condensed lactam derivative | PSEN1, GRIN1, HDAC1 | HTT 934/4885LMNA 2652/4885SMN1; SMN2 280/4885 |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | TNF, IL6, IL1A | HTT 3745/4885LMNA 3905/4885SMN1; SMN2 3917/4885 |
| US-11466007-B2 | Substituted lactams showing serotonin 5-HT receptor activity | HTR1A, HTR5A, TPH1 | HTT 842/4885LMNA 4571/4885SMN1; SMN2 1775/4885 |
| US-20230008875-A1 | SUBSTITUTED LACTAMS SHOWING SEROTONIN 5-HT RECEPTOR ACTIVITY | HTR1A, HTR5A, TPH1 | HTT 842/4885LMNA 4571/4885SMN1; SMN2 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.